CareRx (TSE:CRRX) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
CareRx Corporation has reported its financial results for Q2 2024, showing an increase in adjusted EBITDA to $7.5 million despite a slight revenue dip from the previous year. The Company also faced a net loss of $1.4 million, attributed to a one-off impairment charge related to the sale of a non-core pharmacy operation. CareRx continues to drive efficiencies and manage costs to strengthen its market position in the pharmacy services sector.
For further insights into TSE:CRRX stock, check out TipRanks’ Stock Analysis page.